2012; Peto et al. 2022). With 249 million cases of malaria and 608,000 deaths (97% of which in Africa), genetically guided dose adjustments of amodiaquine remain of utmost clinical importance. Based on population allele frequencies, the rate of CYP2C8 PMs, as defined here by homozygosity or compound heterozygosity of CYP2C8*2 and CYP2C8*3, is calculated to reach up to 13.6% in African countries, such as the Congo, while the fraction of intermediate metabolizers (IMs) is even higher (up to 46.5%) (Peko et al. 2019). This evidence concerns the gene CYP2C8 and malaria.